Analisis Pengelolaan Modal Kerja Dalam USAha Menjaga Likuiditas Dan Profitabilitas Perusahaan (Studi Kasus Pada PT. Armada Pagora Jaya Kediri Periode 2011-2013)

Working capital management is a company activities that aim to regulate and supervise the financial state of the company, especially in current assets and current liabilities for the company to achieve the desired goal. The management of working capital management was intended to find out whether the company can be in a State of excess working capital or working capital deficiency, so that it can manage its capital in a balanced way and get optimal profit. Ratio analysis is used the ratio of liquidity, profitability ratio, debt ratio and activity ratio. The purpose of this research is to know the condition of working capital and working capital management PT. Armada Pagora Jaya Kediri Period 2011-2013. Results of analysis showed that the Net Working Capital the company achieved for 2011 amounting to Rp 6.879.044.889. The year 2012 is amounting to Rp 6.806.565.870 and 2013 Net Working Capital which amounted to Rp 5.532.452.544. Planning sales in 2014 rising 2% in the amount Rp 81.985.934.591 with motorcycle sold 4.371 units. The planning of profit generated by 2014 which is amounting to Rp. 2.109.610.555

Politik Pemilih Muda: Partisipasi Politik Anak Muda di Pekanbaru, Jakarta, Cirebon, Palu dan Jayapura

Partisipasi politik didefinisikan sebagai aktivitas warga negara, termasuk di dalamnya anak muda berusia 15-30 tahun, dengan maksud mempengaruhi tindakan pemerinah, baik secara langsung dengan memberikan masukan terhadap implementasi kebijakan publik, maupun secara tidak langsung dengan memberikan suara pada pemilihan pemangku kebijakan. Tidak terbatas hanya dalam ranah pemilu saja, partisipasi politik seseorang bisa dalam beragam bentuk; mencalonkan diri menjadi ketua organisasi, memberikan saran/kritik terhadap suatu kebijakan, demonstrasi, membuat petisi, atau civil disobedience. Tingkat partisipasi politik anak muda tentu dipengaruhi oleh banyak faktor, diantaranya adalah keterpaparan terhadap pengetahuan Hak Asasi Manusia (HAM), keterpaparan media, ikatan keluarga, dan keaktifan dalam berorganisasi

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

BACKGROUND: The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS: In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month. Patients were excluded from the trial if they had a history of life-threatening or unstable asthma. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization). Noninferiority of fluticasone-salmeterol to fluticasone alone was defined as an upper boundary of the 95% confidence interval for the risk of the primary safety end point of less than 2.0. The efficacy end point was the first severe asthma exacerbation. RESULTS: Of 11,679 patients who were enrolled, 67 had 74 serious asthma-related events, with 36 events in 34 patients in the fluticasone-salmeterol group and 38 events in 33 patients in the fluticasone-only group. The hazard ratio for a serious asthma-related event in the fluticasone-salmeterol group was 1.03 (95% confidence interval [CI], 0.64 to 1.66), and noninferiority was achieved (P=0.003). There were no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthma-related intubation. The risk of a severe asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-only group (hazard ratio, 0.79; 95% CI, 0.70 to 0.89), with at least one severe asthma exacerbation occurring in 480 of 5834 patients (8%) in the fluticasone-salmeterol group, as compared with 597 of 5845 patients (10%) in the fluticasone-only group (P<0.001). CONCLUSIONS: Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of serious asthma-related events than did those who received fluticasone alone. Patients receiving fluticasone-salmeterol had fewer severe asthma exacerbations than did those in the fluticasone-only group